[HTML][HTML] Peptide-based delivery of therapeutics in cancer treatment

T Samec, J Boulos, S Gilmore, A Hazelton… - Materials Today Bio, 2022 - Elsevier
Current delivery strategies for cancer therapeutics commonly cause significant systemic side
effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor …

pH-sensitive endosomolytic peptides in gene and drug delivery: Endosomal escape and current challenges

A Ahmad, JM Khan - Journal of Drug Delivery Science and Technology, 2022 - Elsevier
Numerous endosomolytic agents have been developed to facilitate nanoparticle escape
from the endosome and prevent destruction in the lysosome. Many endosomolytic agents …

Self-assembly of an aptamer-decorated chimeric peptide nanocarrier for targeted cancer gene delivery

S Dehghani, M Alibolandi, ZA Tehranizadeh… - Colloids and Surfaces B …, 2021 - Elsevier
Highlights•KALA-LMWP-NLS chimeric peptide (KLN) was designed and expressed in E. coli
Bl21.•KLN/pDNA/Aptamer nanoparticles were synthesized using electrostatic self …

A cathepsin B/GSH dual-responsive fluorinated peptide for effective siRNA delivery to cancer cells

Z Shi, Y Yang, Z Guo, S Feng, Y Wan - Bioorganic Chemistry, 2023 - Elsevier
Small interfering RNA (siRNA) can be exploited to silence specific genes associated with
cancer development, and successful siRNA therapy is highly dependent on the efficiency of …

Targeting the gastrin-releasing peptide receptor (GRP-R) in cancer therapy: Development of bombesin-based peptide–drug conjugates

J Gomena, B Vári, R Oláh-Szabó, B Biri-Kovács… - International Journal of …, 2023 - mdpi.com
Targeted tumour therapy has proved to be an efficient alternative to overcome the limitations
of conventional chemotherapy. Among several receptors upregulated in cancer cells, the …

Peptide-based targeted polymeric nanoparticles for siRNA delivery

WM Hussein, YS Cheong, C Liu, G Liu… - …, 2019 - iopscience.iop.org
The development of polymer-based nanoparticulate delivery systems for siRNA is important
for the clinical success of gene therapy. However, there are some major drawbacks that …

Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin (9-39)

E Collado Camps, SAM van Lith, A Kip… - European Journal of …, 2023 - Springer
Purpose Exendin, an analogue of the glucagon-like peptide 1 (GLP1), is an excellent tracer
for molecular imaging of pancreatic beta cells and beta cell-derived tumours. The commonly …

Development of irgd-modified peptide carriers for suicide gene therapy of uterine leiomyoma

A Egorova, S Shtykalova, A Selutin, N Shved… - Pharmaceutics, 2021 - mdpi.com
Uterine leiomyoma (UL) is one of the most common benign tumors in women that often
leads to many reproductive complications. Suicide genetherapy was suggested as a …

Peptide-based non-viral gene delivery: A comprehensive review of the advances and challenges

K Xiang, Y Li, H Cong, B Yu, Y Shen - International Journal of Biological …, 2024 - Elsevier
Gene therapy is the most effective treatment option for diseases, but its effectiveness is
affected by the choice and design of gene carriers. The genes themselves have to pass …

[HTML][HTML] In vitro and in vivo evaluation of Bombesin-MMAE conjugates for targeted tumour therapy

J Gomena, D Modena, P Cordella, B Vári… - European Journal of …, 2024 - Elsevier
Targeted tumour therapy has proved to be an efficient alternative to overcome the limitations
of conventional chemotherapy. The upregulation of the bombesin receptor 2 (BB2) in …